PCS2: Preventing Cardiac Sequelae in Pediatric Cancer Survivors
Study Details
Study Description
Brief Summary
Cancer therapy can place childhood cancer survivors at increased risk for heart disease which can lead to significant illness or early death. Interventions that occur late in the evolution of treatment-related heart disease are usually ineffective at preventing its progression to death or heart transplant. Our team will work in several research cores to test new imaging and biomarker methods that will lead to earlier detection of heart disease before clinical symptoms develop or it become apparent on standard imaging tests. We will evaluate the importance of genetic differences between individuals in determining who is at greatest risk of developing heart disease as a result of exposure to cardiotoxic agents. We will combine this genetic information with the novel imaging and biomarker methods to predict which children are at particular risk. These vulnerable children can then be targeted by modifying their cancer therapy to reduce their exposure to cardiac toxins, or introducing medications that protect the heart from chemotherapy damage. This team brings together the expertise of clinicians and scientists in pediatric oncology, pediatric and adult cardiology, radiation oncology, genetics, and biostatistics. This is a cross-Canada initiative that will leverage the latest knowledge about cardiac toxicity and create a resource for ongoing research into this important cause of morbidity and mortality in childhood cancer survivors.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
This is a multi-centre observational cohort study that will be conducted at The Hospital for Sick Children (Toronto), Princess Margaret Hospital (Toronto), McMaster Children's Hospital (Hamilton), London Health Sciences Centre (London), The Children's Hospital of Eastern Ontario (Ottawa) and The Children's Hospital of Orange County (Orange County, California).
The study will address the current limitations in prediction and early diagnosis of anthracycline-induced heart disease. This will be accomplished by the following 3 collaborative cores:
Core 1 (Genomics) will focus on determining which children are most susceptible to treatment-related cardiac toxicity by assessing genes in pathways related to anthracycline absorption, distribution, metabolism, and excretion, as well identifying genes in pathways known to be important in the cardiac response to injury.
Core 2 (Biomarkers) will explore whether existing and novel biomarkers allow for more accurate diagnosis of acute and late treatment-related cardiac toxicity. The core will use a human stem cell platform for discovery of novel biomarkers of anthracycline cardiac damage that will be evaluated in our clinical cohort.
Core 3 (Cardiac imaging) will focus on the evaluation of new echocardiographic and CMR techniques aimed at early identification of cardiac damage after anthracycline exposure.
It will investigate whether changes in cardiac function immediately after anthracycline administration predict which patients will develop progressive cardiac disease over time, and it will explore disease progression through the longitudinal evaluation of innovative echocardiographic parameters of remodeling and dysfunction in CCS exposed to anthracyclines.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Acute Cohort Patients newly diagnosed with cancer who will be receiving anthracycline chemotherapy |
|
| Survivor Cohort Survivors of childhood cancer who are at least 3 years or more from their last dose of anthracycline therapy. |
Outcome Measures
Primary Outcome Measures
- Cardiac Remodeling [one year after last dose of anthracycline therapy in Acute Cohort; anytime during 2 year follow up in Survivor Cohort]
The presence of one or more of the following: Cardiac Remodeling defined as Left Ventricular Posterior Wall Thickness (LVPWT) or Thickness to Dimension Ratio (TDR) z-score <-2.0 or a reduction in LVPWT or TDR z-score by at least 1 standard deviation compared to baseline; or Reduced left ventricular ejection fraction (LV EF) (<55%); or Symptomatic heart failure graded using New York Heart Association (NYHA) classification (or Ross heart failure class at least 2 in infants less than 2 years old)
Eligibility Criteria
Criteria
ACUTE COHORT:
Inclusion Criteria:
-
Aged <18 years at time of cancer diagnosis
-
Diagnosed with a new malignancy (patients with a history of a prior malignancy wlil be eligible if they have not received any anthracycline chemotherapy or chest radiation)
-
Cancer treatment plan will require therapy with at least one dose of any anthracycline
-
Planned to have all pre-anthracycline echocardiograms (ECHO) at the recruiting site
-
Normal cardiac functioning prior to initiation of anthracycline therapy (LV EF > 55%)
-
Patients who are uncooperative during the ECHO without sedation or anesthesia will be included in the study. However, these patients will only undergo clinically indicated echocardiograms, with no echocardiograms added for purely research purposes
-
Provision of signed informed consent by the patient and/or patient's legal guardian
Exclusion Criteria:
-
Patients who were previously treated with anthracycline chemotherapy or radiation to the chest.
-
Significant congenital heart defects, including patients with any other congenital cardiac abnormality, except those with a patent foramen ovale or a small ASD. Patients with familial cardiomyopathies (hypertrophic, dilated and restrictive) will be excluded.
SURVIVOR COHORT:
Inclusion Criteria:
-
Aged < 18 years at time of cancer diagnosis
-
Previously diagnosed with cancer and currently in remission
-
Patients whose prior treatment plan included therapy with at least one dose of any anthracycline
-
Patients who completed their final dose of anthracycline at least 3 years ago
-
Routinely followed at the recruiting site approximately ever 12 months
Exclusion Criteria
-
Prior allogeneic stem cell transplant
-
Significant congenital heart defects, including patients with any other congenital cardiac abnormality, except those with a patent foramen ovale or a small ASD. Patients with familial cardiomyopathies (hypertrophic, dilated and restrictive) will be excluded.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Children's Hospital of Orange County | Orange | California | United States | 92868 |
| 2 | McMaster Children's Hospital | Hamilton | Ontario | Canada | |
| 3 | London Health Sciences Centre | London | Ontario | Canada | |
| 4 | Children's Hospital of Eastern Ontario | Ottawa | Ontario | Canada | |
| 5 | SickKids | Toronto | Ontario | Canada | M5G1XE |
| 6 | Princess Margaret Hospital | Toronto | Ontario | Canada | M5T2M9 |
Sponsors and Collaborators
- The Hospital for Sick Children
- Canadian Institutes of Health Research (CIHR)
- Ontario Institute for Cancer Research
- Pediatric Oncology Group of Ontario
- C17 Council
- Ottawa Heart Institute Research Corporation
- Montreal Heart Institute
- McMaster Children's Hospital
- Children's Hospital of Eastern Ontario
- London Health Sciences Centre
- Children's Hospital of Orange County
- Princess Margaret Hospital, Canada
Investigators
- Principal Investigator: Paul C Nathan, M.D., The Hospital for Sick Children
- Principal Investigator: Mark Greenberg, M.D., The Hospital for Sick Children
- Principal Investigator: Seema Mital, M.D., The Hospital for Sick Children
- Principal Investigator: Luc Mertens, M.D., The Hospital for Sick Children
- Principal Investigator: Paul Kantor, M.D., University of Alberta/Stollery Children's Hospital
- Principal Investigator: Peter Liu, M.D., Ottawa Heart Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1000032746